Inventiva (IVA) EBITDA Margin (2020 - 2022)

Inventiva (IVA) recorded quarterly EBITDA Margin of 6.06% in Q4 2022, up 99.97% quarter-over-quarter from 21021.54% in Q2 2021.

Inventiva (IVA) EBITDA Margin (2020 - 2022) Analysis & Trends

Inventiva's EBITDA Margin history runs 3 years deep, the most recent figure standing at 6.06% for Q4 2022.

  • In Q4 2022, EBITDA Margin changed N/A year-over-year to 6.06%; the TTM figure through Dec 2022 stood at 5.69% (changed N/A YoY), while the FY2025 annual figure was 3145.51%, down 314474.0% from the prior year.
  • EBITDA Margin was 6.06% for Q4 2022 at Inventiva, up from 21021.54% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.06% in Q4 2022 to a low of 21021.54% in Q2 2021.
  • Historically, EBITDA Margin has averaged 10851.51% across 3 years, with a median of 11972.97% in 2020.
  • Biggest YoY gain for EBITDA Margin was 561330 bps in 2021; the steepest drop was 904857 bps in 2021.
  • A 3-year view of EBITDA Margin shows it stood at 11972.97% in 2020, then plunged by 76 bps to 21021.54% in 2021, then surged by 100 bps to 6.06% in 2022.
  • The last three EBITDA Margin figures came in at 6.06% (Q4 2022), 21021.54% (Q2 2021), and 13435.14% (Q1 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn -6.43%
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 38.10%
9 Abivax 95.45 Bn 95.45 Bn - -
10 Inventiva 8.93 Mn -259.80 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 -6.06%
Jun 30, 2021 -21,021.54%
Mar 31, 2021 -13,435.14%
Jun 30, 2020 -11,972.97%
Mar 31, 2020 -7,821.84%